CompletedNot Applicable

Real-world Study of Dedifferentiated Liposarcoma Patients in China

China1,390 participantsStarted 2024-03-13

Plain-language summary

This study will characterize patients with dedifferentiated liposarcoma (DDLPS) in China, including an understanding of demographic, and clinical characteristics as well as treatment patterns and clinical outcomes associated with the current real-world treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Patient has two or more documented clinical visits in the National Anti-Tumor Drug Surveillance System (NATDSS) network on or after January 1, 2013. * Patient has a confirmed diagnosis of dedifferentiated liposarcoma (DDLPS) during his/her lifetime. * At least 18 years old at the date of initial diagnosis. No exclusion criteria are applied.

What they're measuring

Cohort 1: Overall Survival

Timeframe: Time from index date until the earliest record of death or end of the study period, up to 10 years.

Trial details

NCT IDNCT06115681

SponsorBoehringer Ingelheim

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2024-05-15

Results submitted2025-05-14

View on ClinicalTrials.gov More Dedifferentiated Liposarcoma trials